Moderna, Inc. (MRNA)
NASDAQ: MRNA · Real-Time Price · USD
45.94
+0.22 (0.48%)
At close: Apr 30, 2026, 4:00 PM EDT
46.35
+0.41 (0.89%)
After-hours: Apr 30, 2026, 7:59 PM EDT
Moderna Revenue
In the year 2025, Moderna had annual revenue of $1.94B, down -39.93%. Moderna had revenue of $678.00M in the quarter ending December 31, 2025, a decrease of -29.81%.
Revenue (ttm)
$1.94B
Revenue Growth
-39.93%
P/S Ratio
9.37
Revenue / Employee
$413,617
Employees
4,700
Market Cap
18.22B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.94B | -1.29B | -39.93% |
| Dec 31, 2024 | 3.24B | -3.61B | -52.75% |
| Dec 31, 2023 | 6.85B | -12.42B | -64.45% |
| Dec 31, 2022 | 19.26B | 792.00M | 4.29% |
| Dec 31, 2021 | 18.47B | 17.67B | 2,200.25% |
| Dec 31, 2020 | 803.00M | 743.00M | 1,238.33% |
| Dec 31, 2019 | 60.00M | -75.07M | -55.58% |
| Dec 31, 2018 | 135.07M | -70.76M | -34.38% |
| Dec 31, 2017 | 205.83M | 97.43M | 89.88% |
| Dec 31, 2016 | 108.40M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Incyte | 5.36B |
| Jazz Pharmaceuticals | 4.27B |
| Genmab | 3.72B |
| BioNTech SE | 3.37B |
| Exelixis | 2.32B |
| Ionis Pharmaceuticals | 1.06B |
| Madrigal Pharmaceuticals | 958.40M |
| Ascendis Pharma | 845.52M |
MRNA News
- 6 days ago - CureVac sues Moderna for patent infringement over COVID-19 vaccines - Reuters
- 9 days ago - Moderna starts late-stage trial of bird flu vaccine in US, UK - Reuters
- 9 days ago - Moderna Announces Initiation of Phase 3 Study of Investigational mRNA Pandemic Influenza Vaccine Candidate - Accesswire
- 9 days ago - Moderna Announces Data to be Presented at 2026 ASCO Annual Meeting - Accesswire
- 9 days ago - Moderna wins EU approval for combined flu, COVID shot for older adults - Reuters
- 9 days ago - Moderna Receives European Commission Marketing Authorization for mCOMBRIAX, Moderna's mRNA Combination Vaccine Against Influenza and COVID-19 - Accesswire
- 9 days ago - Moderna to Present at Upcoming Conferences in May 2026 - Accesswire
- 13 days ago - Moderna to Present Phase 1/2 Data on Its Investigational Cancer Antigen Therapy mRNA-4359 as First-Line Therapy in Combination with Pembrolizumab in Locally Advanced or Metastatic Melanoma at the 2026 AACR Annual Meeting - Accesswire